Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 116 articles: HTML format

Single Articles

June 2020
1. JOCHEMS SHJ, Stattin P, Haggstrom C, Jarvholm B, et al
   Height, body mass index, and prostate cancer risk and mortality by way of detection and cancer risk category.
   Int J Cancer. 2020 Jun 11. doi: 10.1002/ijc.33150.
   PubMed     Abstract available
   
   
   
2. WENDEU-FOYET MG, Cenee S, Koudou Y, Tretarre B, et al
   Circadian genes polymorphisms, night work and prostate cancer risk: findings from the EPICAP study.
   Int J Cancer. 2020 Jun 7. doi: 10.1002/ijc.33139.
   PubMed     Abstract available
   
   
   May 2020
3. MEYERS TJ, Weiner AB, Graff RE, Desai AS, et al
   Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study.
   Int J Cancer. 2020 May 13. doi: 10.1002/ijc.33048.
   PubMed     Abstract available
   
   
   
4. REMMERS S, Roobol MJ
   Personalized strategies in population screening for prostate cancer.
   Int J Cancer. 2020 May 11. doi: 10.1002/ijc.33045.
   PubMed     Abstract available
   
   
   
5. BORKOWETZ A, Froehner M, Rauner M, Conrad S, et al
   Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.
   Int J Cancer. 2020;146:2619-2627.
   PubMed     Abstract available
   
   
   April 2020
6. HURWITZ LM, Yeboah ED, Biritwum RB, Tettey Y, et al
   Overall and abdominal obesity and prostate cancer risk in a West African population: an analysis of the Ghana Prostate Study.
   Int J Cancer. 2020 Apr 29. doi: 10.1002/ijc.33026.
   PubMed     Abstract available
   
   
   
7. NGUYEN-DUMONT T, MacInnis RJ, Steen JA, Theys D, et al
   Rare germline genetic variants and risk of aggressive prostate cancer.
   Int J Cancer. 2020 Apr 27. doi: 10.1002/ijc.33024.
   PubMed     Abstract available
   
   
   
8. GERKE JS, Orth MF, Tolkach Y, Romero-Perez L, et al
   Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
   Int J Cancer. 2020;146:2036-2046.
   PubMed     Abstract available
   
   
   March 2020
9. WU B, Lu X, Shen H, Yuan X, et al
   Intratumoral heterogeneity and genetic characteristics of prostate cancer.
   Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32961.
   PubMed     Abstract available
   
   
   
10. OHISHI T, Abe H, Sakashita C, Saqib U, et al
    Inhibition of mitochondria ATP synthase suppresses prostate cancer growth through reduced insulin-like growth factor-1 secretion by prostate stromal cells.
    Int J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32959.
    PubMed     Abstract available
    
    
    December 2019
11. ERSVAER E, Hveem TS, Vlatkovic L, Brennhovd B, et al
    Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32832.
    PubMed     Abstract available
    
    
    November 2019
12. WATTS EL, Goldacre R, Key TJ, Allen NE, et al
    Hormone-related diseases and prostate cancer: an English national record linkage study.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32808.
    PubMed     Abstract available
    
    
    
13. LAHEURTE C, Thiery-Vuillemin A, Calcagno F, Legros A, et al
    Metronomic cyclophosphamide induces regulatory T cells depletion and PSA specific T cells reactivation in patients with biochemical recurrent prostate cancer.
    Int J Cancer. 2019 Nov 20. doi: 10.1002/ijc.32803.
    PubMed     Abstract available
    
    
    
14. WU Z, Nguyen NH, Wang D, Lynch BM, et al
    Social connectedness and mortality after prostate cancer diagnosis: a prospective cohort study.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32786.
    PubMed     Abstract available
    
    
    October 2019
15. LAI SW, Kuo YH, Liao KF
    Calcium channel blockers therapy and the risk of prostate cancer death.
    Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32748.
    PubMed    
    
    
    
16. SANTALA EE, Rannikko A, Murtola TJ
    Reply to "Calcium channel blockers therapy and the risk of prostate cancer death".
    Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32745.
    PubMed    
    
    
    
17. STIKBAKKE E, Richardsen E, Knutsen T, Wilsgaard T, et al
    Inflammatory serum markers and risk and severity of prostate cancer. The PROCA-life Study.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32718.
    PubMed     Abstract available
    
    
    
18. WARD MM
    Chronic Oral Anticoagluation and Risk of Prostate Cancer: Evidence of Detection Bias.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32712.
    PubMed     Abstract available
    
    
    September 2019
19. ZHANG S, Sugawara Y, Chen S, Beelman RB, et al
    Mushroom consumption and incident risk of prostate cancer in Japan: A pooled analysis of the Miyagi Cohort Study and the Ohsaki Cohort Study.
    Int J Cancer. 2019 Sep 4. doi: 10.1002/ijc.32591.
    PubMed     Abstract available
    
    
    August 2019
20. SINGH V, Jaiswal PK, Ghosh I, Koul HK, et al
    Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.
    Int J Cancer. 2019;145:1055-1067.
    PubMed     Abstract available
    
    
    
21. LARSSON P, Syed Khaja AS, Semenas J, Wang T, et al
    The functional inter-link between AR and MMP9/VEGF signaling axis is mediated through PIP5K1alpha/pAKT in prostate cancer.
    Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32607.
    PubMed     Abstract available
    
    
    July 2019
22. HASHIM D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, et al
    Family history of prostate cancer and the incidence of ERG- and PTEN-defined prostate cancer.
    Int J Cancer. 2019 Jul 18. doi: 10.1002/ijc.32577.
    PubMed     Abstract available
    
    
    
23. 
    Retraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonster
    Int J Cancer. 2019;145:E12.
    PubMed     Abstract available
    
    
    
24. SAWADA Y, Kikugawa T, Iio H, Sakakibara I, et al
    GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer.
    Int J Cancer. 2019 Jul 5. doi: 10.1002/ijc.32554.
    PubMed     Abstract available
    
    
    
25. BECKER F, Joerg V, Hupe MC, Roth D, et al
    Increased Mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
    Int J Cancer. 2019 Jul 4. doi: 10.1002/ijc.32551.
    PubMed     Abstract available
    
    
    
26. BI L, Xie C, Yao M, Thae Hnit SS, et al
    The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells.
    Int J Cancer. 2019;145:164-178.
    PubMed     Abstract available
    
    
    June 2019
27. LI H, Kim C, Liu W, Zhu J, et al
    Olfactomedin 4 downregulation is associated with tumor initiation, growth, and progression in human prostate cancer.
    Int J Cancer. 2019 Jun 26. doi: 10.1002/ijc.32535.
    PubMed     Abstract available
    
    
    
28. KOGEVINAS M, Espinosa A, Papantoniou K, Aragones N, et al
    Prostate cancer risk decreases following cessation of night shift work.
    Int J Cancer. 2019 Jun 24. doi: 10.1002/ijc.32528.
    PubMed     Abstract available
    
    
    
29. DU Z, Hopp H, Ingles SA, Huff C, et al
    A Genome-wide Association Study of Prostate Cancer in Latinos.
    Int J Cancer. 2019 Jun 21. doi: 10.1002/ijc.32525.
    PubMed     Abstract available
    
    
    
30. BOWDEN P, See AW, Frydenberg M, Haxhimolla H, et al
    Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32509.
    PubMed     Abstract available
    
    
    May 2019
31. ALSHALALFA M, Liu Y, Wyatt AW, Gibb EA, et al
    Characterization of Transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32430.
    PubMed     Abstract available
    
    
    
32. STRAND SH, Bavafaye-Haghighi E, Kristensen H, Rasmussen A, et al
    A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32427.
    PubMed     Abstract available
    
    
    
33. GAO X, Wilsgaard T, Jansen EH, Xuan Y, et al
    Serum total thiol levels and the risk of lung, colorectal, breast and prostate cancer: A prospective case-cohort study.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32428.
    PubMed     Abstract available
    
    
    
34. SHI X, Zhang W, Nian X, Lu X, et al
    The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
    Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32422.
    PubMed     Abstract available
    
    
    
35. MITRAN B, Rinne SS, Konijnenberg MW, Maina T, et al
    Trastuzumab co-treatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist (177) Lu-DOTAGA-PEG2 -RM26.
    Int J Cancer. 2019 May 11. doi: 10.1002/ijc.32401.
    PubMed     Abstract available
    
    
    April 2019
36. WANG R, Chu GC, Wang X, Wu JB, et al
    Establishment and characterization of a prostate cancer cell line from a prostatectomy specimen for the study of cellular interaction.
    Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32370.
    PubMed     Abstract available
    
    
    
37. GORODETSKA I, Lukiyanchuk V, Peitzsch C, Kozeretska I, et al
    BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32323.
    PubMed     Abstract available
    
    
    
38. SCHMIDT JA, Fensom GK, Rinaldi S, Scalbert A, et al
    Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: a prospective study of 3057 matched case-control sets from EPIC.
    Int J Cancer. 2019 Apr 5. doi: 10.1002/ijc.32314.
    PubMed     Abstract available
    
    
    
39. RIEMANN A, Reime S, Thews O
    Acidic extracellular environment affects miRNA expression in tumors in vitro and in vivo.
    Int J Cancer. 2019;144:1609-1618.
    PubMed     Abstract available
    
    
    March 2019
40. FREDSOE J, Rasmussen AKI, Mouritzen P, Borre M, et al
    A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.
    Int J Cancer. 2019 Mar 23. doi: 10.1002/ijc.32296.
    PubMed     Abstract available
    
    
    
41. BRUREAU L, Emeville E, Helissey C, Thome JP, et al
    Endocrine Disrupting-Chemicals and Biochemical Recurrence of Prostate Cancer after Prostatectomy: A cohort study in Guadeloupe (French West Indies).
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32287.
    PubMed     Abstract available
    
    
    
42. SUGAWARA T, Baumgart SJ, Nevedomskaya E, Reichert K, et al
    Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Int J Cancer. 2019 Mar 3. doi: 10.1002/ijc.32242.
    PubMed     Abstract available
    
    
    February 2019
43. PEREZ-CORNAGO A, Huybrechts I, Appleby PN, Schmidt JA, et al
    Intake of Individual Fatty Acids and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32233.
    PubMed     Abstract available
    
    
    
44. MARIN-AGUILERA M, Reig O, Mila-Guasch M, Font A, et al
    The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32238.
    PubMed     Abstract available
    
    
    
45. HUANG J, Mondul AM, Weinstein SJ, Derkach A, et al
    Prospective Serum Metabolomic Profiling of Lethal Prostate Cancer.
    Int J Cancer. 2019 Feb 18. doi: 10.1002/ijc.32218.
    PubMed     Abstract available
    
    
    January 2019
46. WENDEU-FOYET MG, Koudou Y, Cenee S, Tretarre B, et al
    Circadian genes and risk of prostate cancer: findings from the EPICAP study.
    Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32149.
    PubMed     Abstract available
    
    
    
47. LINDBERG A, Talala K, Kujala P, Stenman UH, et al
    Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32129.
    PubMed     Abstract available
    
    
    
48. LIU Q, Wang G, Li Q, Jiang W, et al
    Polycomb Group Proteins EZH2 and EED Directly Regulate Androgen Receptor in Advanced Prostate Cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32118.
    PubMed     Abstract available
    
    
    December 2018
49. GAO X, Wilsgaard T, Jansen EH, Holleczek B, et al
    Pre-diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta-analysis of two large population-based studies.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32073.
    PubMed     Abstract available
    
    
    
50. PARRY MG, Sujenthiran A, Cowling TE, Nossiter J, et al
    Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.
    Int J Cancer. 2018 Dec 14. doi: 10.1002/ijc.32068.
    PubMed     Abstract available
    
    
    
51. MO RJ, Han ZD, Liang YK, Ye JH, et al
    Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8(+) tumor-associated lymphocytes and poor prognosis in prostate cancer.
    Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32061.
    PubMed     Abstract available
    
    
    
52. GRAF ME, Sookthai D, Johnson T, Schubel R, et al
    Pre-diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study.
    Int J Cancer. 2018;143:2659-2667.
    PubMed     Abstract available
    
    
    November 2018
53. KOCHER S, Beyer B, Lange T, Nordquist L, et al
    A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32018.
    PubMed     Abstract available
    
    
    
54. SROUR B, Plancoulaine S, Andreeva VA, Fassier P, et al
    Circadian nutritional behaviours and cancer risk: New insights from the NutriNet-sante prospective cohort study: Disclaimers.
    Int J Cancer. 2018;143:2369-2379.
    PubMed     Abstract available
    
    
    
55. YUAN C, Shui IM, Wilson KM, Stampfer MJ, et al
    Circulating 25-hydroxyvitamin D, vitamin D binding protein, and risk of advanced and lethal prostate cancer.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31966.
    PubMed     Abstract available
    
    
    October 2018
56. BEYNON R, Richmond RC, Santos Ferreira DL, Ness AR, et al
    Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial.
    Int J Cancer. 2018 Oct 16. doi: 10.1002/ijc.31929.
    PubMed     Abstract available
    
    
    
57. ZHANG AY, Chiam K, Haupt Y, Fox S, et al
    An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy.
    Int J Cancer. 2018 Oct 4. doi: 10.1002/ijc.31906.
    PubMed     Abstract available
    
    
    September 2018
58. OMARI A, Nastaly P, Stoupiec S, Balabas A, et al
    Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR and tumor progression in prostate cancer.
    Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31905.
    PubMed     Abstract available
    
    
    
59. JI J, Sundquist J, Sundquist K
    Use of terbinafine and risk of death in patients with prostate cancer: A population-based cohort study.
    Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31901.
    PubMed     Abstract available
    
    
    
60. KRISTENSEN KB, Jensen PH, Skriver C, Friis S, et al
    Use of vitamin K antagonists and risk of prostate cancer: Meta-analysis and nationwide case-control study.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31886.
    PubMed     Abstract available
    
    
    
61. TSANG SH, Peisch SF, Rowan B, Markt SC, et al
    Association between Trichomonas vaginalis and prostate cancer mortality.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31885.
    PubMed     Abstract available
    
    
    
62. HU B, Hu H, Yin M, Sun Z, et al
    Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31877.
    PubMed     Abstract available
    
    
    
63. BRADBURY KE, Appleby PN, Tipper SJ, Travis RC, et al
    Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31854.
    PubMed     Abstract available
    
    
    
64. LEE KH, Hong S, Kang M, Jeong CW, et al
    Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31843.
    PubMed     Abstract available
    
    
    August 2018
65. KAIKKONEN E, Rantapero T, Zhang Q, Taimen P, et al
    ANO7 is associated with aggressive prostate cancer.
    Int J Cancer. 2018 Aug 29. doi: 10.1002/ijc.31746.
    PubMed     Abstract available
    
    
    
66. MASSILLO C, Dalton GN, Porretti J, Scalise GD, et al
    CTBP1/CYP19A1/Estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31773.
    PubMed     Abstract available
    
    
    
67. LAKSHMANA G, Baniahmad A
    Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31818.
    PubMed     Abstract available
    
    
    
68. SANTALA EE, Rannikko A, Murtola TJ
    Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland - a nationwide cohort study.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31802.
    PubMed     Abstract available
    
    
    
69. BAO C, Pedersen NL, Yang R, Marseglia A, et al
    Diabetes in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2018;143:793-800.
    PubMed     Abstract available
    
    
    
70. COLLINS RJ, Morgan LD, Owen S, Ruge F, et al
    Mechanistic insights of Epithelial Protein Lost in Neoplasm in prostate cancer metastasis.
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31786.
    PubMed     Abstract available
    
    
    July 2018
71. KOGEVINAS M, Espinosa A, Castello A, Gomez-Acebo I, et al
    Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study).
    Int J Cancer. 2018 Jul 17. doi: 10.1002/ijc.31649.
    PubMed     Abstract available
    
    
    
72. SAMPSON N, Brunner E, Weber A, Puhr M, et al
    Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.
    Int J Cancer. 2018;143:383-395.
    PubMed     Abstract available
    
    
    
73. ANDREE KC, Mentink A, Zeune LL, Terstappen LWMM, et al
    Towards a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multi-center study (CTCTrap).
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31752.
    PubMed     Abstract available
    
    
    
74. PEREZ-CORNAGO A, Appleby PN, Boeing H, Gil L, et al
    Circulating isoflavone and lignan concentrations and prostate cancer risk: A meta-analysis of individual participant data from seven prospective studies including 2828 cases and 5593 controls.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31640.
    PubMed     Abstract available
    
    
    June 2018
75. SEN A, Papadimitriou N, Lagiou P, Perez-Cornago A, et al
    Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31634.
    PubMed     Abstract available
    
    
    May 2018
76. HAGGSTROM C, Van Hemelrijck M, Garmo H, Robinson D, et al
    Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31587.
    PubMed     Abstract available
    
    
    April 2018
77. OKI R, Ito K, Suzuki R, Fujizuka Y, et al
    Long-term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population-based PSA screening.
    Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31560.
    PubMed     Abstract available
    
    
    
78. URBIOLA C, Santer FR, Petersson M, van der Pluijm G, et al
    Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.
    Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556.
    PubMed     Abstract available
    
    
    
79. DOAT S, Marous M, Rebillard X, Tretarre B, et al
    Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study.
    Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31565.
    PubMed     Abstract available
    
    
    March 2018
80. BELIC J, Graf R, Bauernhofer T, Cherkas Y, et al
    Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31397.
    PubMed     Abstract available
    
    
    
81. PORRETTI J, Dalton GN, Massillo C, Scalise GD, et al
    CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease.
    Int J Cancer. 2018 Mar 14. doi: 10.1002/ijc.31379.
    PubMed     Abstract available
    
    
    February 2018
82. CUI J, Wang Y, Dong B, Qin L, et al
    Pharmacological Inhibition of the Notch Pathway Enhances the Efficacy of Androgen Deprivation Therapy for Prostate Cancer.
    Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31346.
    PubMed     Abstract available
    
    
    
83. QU S, Xue H, Dong X, Lin D, et al
    Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31310.
    PubMed     Abstract available
    
    
    
84. SHAO Y, Ye G, Ren S, Piao HL, et al
    Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31313.
    PubMed     Abstract available
    
    
    
85. FARRIS MS, Courneya KS, Kopciuk KA, McGregor SE, et al
    Post-diagnosis alcohol intake and prostate cancer survival: A population-based cohort study.
    Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31307.
    PubMed     Abstract available
    
    
    
86. DAWE DE, Ye X, Czaykowski P, Jassal D, et al
    The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study.
    Int J Cancer. 2018 Feb 6. doi: 10.1002/ijc.31295.
    PubMed     Abstract available
    
    
    January 2018
87. TOMIC K, Ventimiglia E, Robinson D, Haggstrom C, et al
    Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31272.
    PubMed     Abstract available
    
    
    
88. ARTHUR R, Williams R, Garmo H, Holmberg L, et al
    Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.
    Int J Cancer. 2018 Jan 11. doi: 10.1002/ijc.31256.
    PubMed     Abstract available
    
    
    
89. WU J, Wilson KM, Stampfer MJ, Willett WC, et al
    A 24-year prospective study of dietary alpha-linolenic acid and lethal prostate cancer.
    Int J Cancer. 2018 Jan 8. doi: 10.1002/ijc.31247.
    PubMed     Abstract available
    
    
    December 2017
90. LUO Y, Azad AK, Karanika S, Basourakos SP, et al
    Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31237.
    PubMed     Abstract available
    
    
    
91. KHAN S, Hicks V, Colditz GA, Kibel AS, et al
    The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence.
    Int J Cancer. 2017 Dec 22. doi: 10.1002/ijc.31229.
    PubMed     Abstract available
    
    
    
92. RIDGE SM, Bhattacharyya D, Dervan E, Naicker SD, et al
    Secreted Factors from Metastatic Prostate Cancer Cells Stimulate Mesenchymal Stem Cell Transition to a Pro-tumourigenic 'Activated' State that Enhances Prostate Cancer Cell Migration.
    Int J Cancer. 2017 Dec 20. doi: 10.1002/ijc.31226.
    PubMed     Abstract available
    
    
    
93. UGGE H, Udumyan R, Carlsson J, Andren O, et al
    Acne in late adolescence and risk of prostate cancer.
    Int J Cancer. 2017 Dec 4. doi: 10.1002/ijc.31192.
    PubMed     Abstract available
    
    
    November 2017
94. GONZALEZ-MENENDEZ P, Hevia D, Mayo JC, Sainz RM, et al
    The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31165.
    PubMed     Abstract available
    
    
    
95. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Abstract available
    
    
    
96. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Abstract available
    
    
    
97. DICKERMAN BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, et al
    Midlife metabolic factors and prostate cancer risk in later life.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31142.
    PubMed     Abstract available
    
    
    October 2017
98. SEIKKULA HA, Kaipia AJ, Ryynanen H, Seppa K, et al
    The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31109.
    PubMed     Abstract available
    
    
    
99. HEIJNSDIJK EAM, Bangma CH, Borras JM, de Carvalho TM, et al
    Summary statement on screening for prostate cancer in Europe.
    Int J Cancer. 2017 Oct 12. doi: 10.1002/ijc.31102.
    PubMed     Abstract available
    
    
    
100. 
     Retraction: 'Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells' by Nobuyuki Kikuno, Hiroaki Shiina, Shinji Urakami, Ken Kawamoto, Hiroshi Hirata, Yuichiro Tanaka, Shahana Majid, Mikio Ig
     Int J Cancer. 2017;141:1492.
     PubMed     Abstract available
     
     
     August 2017
101. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
     Three-year cancer incidence in Blantyre, Malawi (2008-2010).
     Int J Cancer. 2017;141:694-700.
     PubMed     Abstract available
     
     
     
102. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
     Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
     Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
     PubMed     Abstract available
     
     
     July 2017
103. LIN HM, Mahon KL, Weir JM, Mundra PA, et al
     A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer: Authors.
     Int J Cancer. 2017 Jul 25. doi: 10.1002/ijc.30903.
     PubMed     Abstract available
     
     
     
104. WANG B, Lo UG, Wu K, Kapur P, et al
     Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.
     Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30893.
     PubMed     Abstract available
     
     
     
105. WANG K, Chen X, Bird VY, Gerke TA, et al
     Association between Age-Related Reductions in Testosterone and Risk of Prostate Cancer - An Analysis of Patients' Data with Prostatic Diseases.
     Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30882.
     PubMed     Abstract available
     
     
     
106. GU F, Zhang H, Hyland PL, Berndt S, et al
     Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
     Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
     PubMed     Abstract available
     
     
     
107. SCHECHER S, Walter B, Falkenstein M, Macher-Goeppinger S, et al
     Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer.
     Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30864.
     PubMed     Abstract available
     
     
     June 2017
108. AL-QATATI A, Akrong C, Stevic I, Pantel K, et al
     Plasma microRNA signature is associated with risk stratification in prostate cancer patients.
     Int J Cancer. 2017 Jun 1. doi: 10.1002/ijc.30815.
     PubMed     Abstract available
     
     
     May 2017
109. DICKERMAN BA, Ahearn TU, Giovannucci E, Stampfer MJ, et al
     Weight change, obesity, and risk of prostate cancer progression among men with clinically localized prostate cancer.
     Int J Cancer. 2017 May 23. doi: 10.1002/ijc.30803.
     PubMed     Abstract available
     
     
     
110. WANG Y, Freedman JA, Liu H, Moorman PG, et al
     Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.
     Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30787.
     PubMed     Abstract available
     
     
     April 2017
111. POUNIS G, Tabolacci C, Costanzo S, Cordella M, et al
     Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models.
     Int J Cancer. 2017 Apr 24. doi: 10.1002/ijc.30720.
     PubMed     Abstract available
     
     
     
112. PEREZ-CORNAGO A, Travis RC, Appleby PN, Tsilidis KK, et al
     Fruit and vegetable intake and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).
     Int J Cancer. 2017 Apr 17. doi: 10.1002/ijc.30741.
     PubMed     Abstract available
     
     
     
113. ROMAGUERA D, Gracia-Lavedan E, Molinuevo A, de Batlle J, et al
     Adherence to nutrition-based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the MCC-Spain case-control study.
     Int J Cancer. 2017 Apr 5. doi: 10.1002/ijc.30722.
     PubMed     Abstract available
     
     
     March 2017
114. KAWADA T
     Dairy intake and prostate cancer survival.
     Int J Cancer. 2017 Mar 23. doi: 10.1002/ijc.30703.
     PubMed    
     
     
     January 2017
115. LUBIK AA, Nouri M, Truong S, Ghaffari M, et al
     Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
     Int J Cancer. 2017;140:358-369.
     PubMed     Abstract available
     
     
     October 2016
116. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
     Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
     Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: